Toll Free: 1-888-928-9744

Alexion Pharmaceuticals, Inc. - Product Pipeline Review - 2016

Published: Apr 13, 2016 | Pages: 77 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Alexion Pharmaceuticals, Inc. - Product Pipeline Review - 2016

Summary

Global Markets Direct's, ‘Alexion Pharmaceuticals, Inc. - Product Pipeline Review - 2016', provides an overview of the Alexion Pharmaceuticals, Inc.'s pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by Alexion Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Alexion Pharmaceuticals, Inc.
- The report provides overview of Alexion Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Alexion Pharmaceuticals, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Alexion Pharmaceuticals, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to Buy

- Evaluate Alexion Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Alexion Pharmaceuticals, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Alexion Pharmaceuticals, Inc.'s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
 Table of Content
Table of Contents 2 List of Tables 5 List of Figures 5 Alexion Pharmaceuticals, Inc. Snapshot 6 Alexion Pharmaceuticals, Inc. Overview 6 Key Information 6 Key Facts 6 Alexion Pharmaceuticals, Inc. - Research and Development Overview 7 Key Therapeutic Areas 7 Alexion Pharmaceuticals, Inc. - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Pipeline Products - Partnered Products 12 Partnered Products/Combination Treatment Modalities 13 Alexion Pharmaceuticals, Inc. - Pipeline Products Glance 14 Alexion Pharmaceuticals, Inc. - Late Stage Pipeline Products 14 Pre-Registration Products/Combination Treatment Modalities 14 Phase III Products/Combination Treatment Modalities 15 Alexion Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 16 Phase II Products/Combination Treatment Modalities 16 Phase I Products/Combination Treatment Modalities 17 Alexion Pharmaceuticals, Inc. - Early Stage Pipeline Products 18 Preclinical Products/Combination Treatment Modalities 18 Discovery Products/Combination Treatment Modalities 19 Alexion Pharmaceuticals, Inc. - Drug Profiles 20 sebelipase alfa 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 eculizumab 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 ALXN-1101 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 ALXN-1007 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 ALXN-1210 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Monoclonal Antibodies for Undisclosed Indication 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 SBC-103 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 ALXN-5500 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 asfotase alfa 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Drugs for Undisclosed Indications 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Drugs to Inhibit Complement System Protein 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Recombinant Enzymes for Pompe, Fabry and Hunter Diseases 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 SBC-104 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 SBC-105 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 SBC-106 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 SBC-342 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Small Molecules for Orphan Diseases 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Alexion Pharmaceuticals, Inc. - Pipeline Analysis 42 Alexion Pharmaceuticals, Inc. - Pipeline Products by Target 42 Alexion Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 43 Alexion Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 44 Alexion Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 45 Alexion Pharmaceuticals, Inc. - Recent Pipeline Updates 46 Alexion Pharmaceuticals, Inc. - Dormant Projects 69 Alexion Pharmaceuticals, Inc. - Discontinued Pipeline Products 70 Alexion Pharmaceuticals, Inc. - Discontinued Pipeline Products 70 Discontinued Pipeline Product Profiles 70 Cellular Immunotherapy for Central Nervous System 70 pexelizumab 70 Alexion Pharmaceuticals, Inc. - Company Statement 71 Alexion Pharmaceuticals, Inc. - Locations And Subsidiaries 72 Head Office 72 Other Locations & Subsidiaries 72 Appendix 76 Methodology 76 Coverage 76 Secondary Research 76 Primary Research 76 Expert Panel Validation 76 Contact Us 76 Disclaimer 77
List of Tables
Alexion Pharmaceuticals, Inc., Key Information 6 Alexion Pharmaceuticals, Inc., Key Facts 6 Alexion Pharmaceuticals, Inc. - Pipeline by Indication, 2016 8 Alexion Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016 10 Alexion Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016 11 Alexion Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2016 12 Alexion Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2016 13 Alexion Pharmaceuticals, Inc. - Pre-Registration, 2016 14 Alexion Pharmaceuticals, Inc. - Phase III, 2016 15 Alexion Pharmaceuticals, Inc. - Phase II, 2016 16 Alexion Pharmaceuticals, Inc. - Phase I, 2016 17 Alexion Pharmaceuticals, Inc. - Preclinical, 2016 18 Alexion Pharmaceuticals, Inc. - Discovery, 2016 19 Alexion Pharmaceuticals, Inc. - Pipeline by Target, 2016 42 Alexion Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016 43 Alexion Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016 44 Alexion Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016 45 Alexion Pharmaceuticals, Inc. - Recent Pipeline Updates, 2016 46 Alexion Pharmaceuticals, Inc. - Dormant Developmental Projects,2016 69 Alexion Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2016 70 Alexion Pharmaceuticals, Inc., Subsidiaries 72


List of Figures
Alexion Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2016 8 Alexion Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016 10 Alexion Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016 11 Alexion Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2016 12 Alexion Pharmaceuticals, Inc. - Pipeline by Target, 2016 42 Alexion Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016 43 Alexion Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016 44 Alexion Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016 45

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global air traffic control equipment market is projected to reach USD 4.2 billion by 2020, as per a new research report by Radiant Insights, Inc. Mounting price sensitivity among customers with introduction of low fare airlines is expected to drive t

Read More...

Global glycerol market size is likely to exceed USD 3 billion by 2022, as per a new research report by Radiant Insights, Inc. Regulatory push for promoting bio-diesel production is expected to boost glycerol demand over the forecast period, with expe

Read More...

Global polymethyl methacrylate (PMMA) market size is likely to be valued at USD 11.65 billion by 2022; as per a new research report by Radiant Insights, Inc. Increasing spending on advertising & marketing for building strong brand equity and product

Read More...

Global Automated Test Equipment (ATE) market is expected to be valued at USD 4.48 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing design complexity coupled with need for effective testing is expected to drive the gl

Read More...

Global PP (Polypropylene) nonwoven fabric market size is anticipated to be valued at USD 30.6 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing usage of hygiene products such as incontinence products and baby diapers is

Read More...
Choose License Type
Single User - US $1500
Multi User - US $3000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify